Urogen Pharma LtdNASDAQ:URGN
- LAST PRICE13.2200
- TODAY'S CHANGE (%)0.0100 (0.0757%)
- Bid / Lots13.0000/ 2
- Ask / Lots14.8900/ 1
- Open / Previous Close13.2200 / 13.2100
- Day Range
- 52 Week Range
- Volume232,110
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | URGN |
|---|---|---|
| 09:32 ET | 7340 | 13.27 |
| 09:36 ET | 3056 | 13.09 |
| 09:45 ET | 449 | 13.1 |
| 09:48 ET | 400 | 13.09 |
| 09:52 ET | 100 | 13.05 |
| 09:54 ET | 400 | 13.05 |
| 09:56 ET | 500 | 13.12 |
| 09:57 ET | 936 | 13.05 |
| 09:59 ET | 100 | 13.04 |
| 10:01 ET | 1542 | 13.1 |
| 10:03 ET | 2315 | 13.1 |
| 10:06 ET | 583 | 13.1 |
| 10:08 ET | 650 | 13.08 |
| 10:10 ET | 100 | 13.07 |
| 10:17 ET | 600 | 13.04 |
| 10:28 ET | 500 | 13.1 |
| 10:30 ET | 333 | 13.1 |
| 10:32 ET | 800 | 13.07 |
| 10:33 ET | 100 | 13.0662 |
| 10:37 ET | 100 | 13.08 |
| 10:39 ET | 100 | 13.0871 |
| 10:42 ET | 100 | 13.1027 |
| 10:44 ET | 100 | 13.08 |
| 10:48 ET | 5351 | 13.09 |
| 10:50 ET | 300 | 13.09 |
| 10:51 ET | 441 | 13.09 |
| 10:53 ET | 332 | 13.1 |
| 10:57 ET | 10927 | 13.13 |
| 11:00 ET | 806 | 13.17 |
| 11:02 ET | 1664 | 13.16 |
| 11:06 ET | 100 | 13.13 |
| 11:09 ET | 100 | 13.13 |
| 11:13 ET | 600 | 13.13 |
| 11:15 ET | 100 | 13.13 |
| 11:18 ET | 600 | 13.13 |
| 11:20 ET | 400 | 13.12 |
| 11:24 ET | 100 | 13.11 |
| 11:26 ET | 500 | 13.12 |
| 11:27 ET | 150 | 13.11 |
| 11:31 ET | 200 | 13.13 |
| 11:40 ET | 1330 | 13.1 |
| 11:42 ET | 200 | 13.06 |
| 11:44 ET | 100 | 13.055 |
| 11:49 ET | 29451 | 13.22 |
| 11:51 ET | 1665 | 13.345 |
| 11:54 ET | 1566 | 13.255 |
| 11:56 ET | 200 | 13.2425 |
| 11:58 ET | 1244 | 13.31 |
| 12:00 ET | 200 | 13.28 |
| 12:03 ET | 100 | 13.26 |
| 12:07 ET | 300 | 13.26 |
| 12:14 ET | 300 | 13.3 |
| 12:18 ET | 1400 | 13.305 |
| 12:20 ET | 509 | 13.3 |
| 12:21 ET | 856 | 13.28 |
| 12:25 ET | 200 | 13.26 |
| 12:27 ET | 4333 | 13.29 |
| 12:34 ET | 100 | 13.27 |
| 12:36 ET | 100 | 13.27 |
| 12:38 ET | 500 | 13.29 |
| 12:39 ET | 400 | 13.27 |
| 12:41 ET | 100 | 13.24 |
| 12:43 ET | 100 | 13.25 |
| 12:48 ET | 1600 | 13.3 |
| 12:56 ET | 300 | 13.25 |
| 12:57 ET | 100 | 13.29 |
| 12:59 ET | 117 | 13.305 |
| 01:03 ET | 700 | 13.26 |
| 01:17 ET | 100 | 13.23 |
| 01:24 ET | 100 | 13.28 |
| 01:28 ET | 925 | 13.24 |
| 01:30 ET | 100 | 13.25 |
| 01:32 ET | 100 | 13.21 |
| 01:44 ET | 100 | 13.19 |
| 01:46 ET | 200 | 13.1901 |
| 01:48 ET | 1927 | 13.22 |
| 01:53 ET | 865 | 13.21 |
| 01:57 ET | 2909 | 13.23 |
| 02:02 ET | 200 | 13.2201 |
| 02:09 ET | 1023 | 13.24 |
| 02:11 ET | 100 | 13.23 |
| 02:13 ET | 200 | 13.23 |
| 02:15 ET | 100 | 13.225 |
| 02:18 ET | 100 | 13.22 |
| 02:20 ET | 200 | 13.21 |
| 02:22 ET | 1021 | 13.23 |
| 02:24 ET | 100 | 13.21 |
| 02:26 ET | 300 | 13.23 |
| 02:27 ET | 589 | 13.23 |
| 02:36 ET | 325 | 13.23 |
| 02:38 ET | 1100 | 13.28 |
| 02:45 ET | 100 | 13.27 |
| 02:47 ET | 100 | 13.265 |
| 02:51 ET | 300 | 13.285 |
| 02:54 ET | 500 | 13.285 |
| 02:56 ET | 100 | 13.305 |
| 02:58 ET | 100 | 13.3 |
| 03:00 ET | 987 | 13.305 |
| 03:02 ET | 590 | 13.28 |
| 03:03 ET | 305 | 13.23 |
| 03:05 ET | 100 | 13.255 |
| 03:09 ET | 200 | 13.25 |
| 03:12 ET | 2167 | 13.275 |
| 03:14 ET | 1132 | 13.3 |
| 03:16 ET | 400 | 13.28 |
| 03:18 ET | 800 | 13.27 |
| 03:20 ET | 1623 | 13.24 |
| 03:21 ET | 1902 | 13.27 |
| 03:23 ET | 100 | 13.29 |
| 03:25 ET | 100 | 13.29 |
| 03:27 ET | 800 | 13.3 |
| 03:30 ET | 2600 | 13.28 |
| 03:32 ET | 1624 | 13.29 |
| 03:34 ET | 5672 | 13.2 |
| 03:36 ET | 410 | 13.185 |
| 03:38 ET | 500 | 13.16 |
| 03:39 ET | 2068 | 13.16 |
| 03:43 ET | 200 | 13.15 |
| 03:45 ET | 2737 | 13.13 |
| 03:50 ET | 1251 | 13.13 |
| 03:52 ET | 203 | 13.14 |
| 03:54 ET | 1410 | 13.15 |
| 03:56 ET | 2809 | 13.155 |
| 03:57 ET | 6061 | 13.195 |
| 03:59 ET | 6683 | 13.22 |
May 14, 2024
DJ UroGen Pharma Is Maintained at Outperform by Oppenheimer, from 8:35AM ET on Tuesday May 14, 2024 by Dow Jones
8:35AM ET on Tuesday May 14, 2024 by Dow JonesDJ UroGen Pharma Price Target Maintained With a $54.00/Share by HC Wainwright & Co., from 6:34AM ET on Tuesday May 14, 2024 by Dow Jones
6:34AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights, from 8:00AM ET on Monday May 13, 2024 by Dow Jones
8:00AM ET on Monday May 13, 2024 by Dow JonesPress Release: UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights, from 8:00AM ET on Monday May 13, 2024 by Dow Jones
8:00AM ET on Monday May 13, 2024 by Dow Jones
May 7, 2024
UroGen Pharma to Participate at Upcoming Investor Conferences, from 8:00AM ET on Tuesday May 07, 2024 by Dow Jones
8:00AM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Urogen Pharma Ltd | 477.6M | -3.9x | --- |
Editas Medicine Inc | 462.2M | -2.7x | --- |
Y-mAbs Therapeutics Inc | 509.0M | -23.4x | --- |
Alector Inc | 524.3M | -3.9x | --- |
Fate Therapeutics Inc | 443.9M | -2.0x | --- |
ADC Therapeutics SA | 394.4M | -1.5x | --- |
Company Information
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Contact Information
- Headquarters
- 9 Ha'ta'asiya StRA'ANANA, Israel 4365007
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Arie Belldegrun
- President, Chief Executive Officer, Director
- Elizabeth Barrett
- Chief Financial Officer
- Dong Kim
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Jason Smith
- Chief Medical Officer
- Mark Schoenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $477.6M |
|---|---|
Revenue (TTM) | $84.3M |
Shares Outstanding | 36.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-3.39 |
Book Value | $-2.01 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -82.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
